3-氰基-4-羟基苯甲酸乙酯 | 34133-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氰基-4-羟基苯甲酸乙酯
• 英文名称: ethyl 4-hydroxy-3-cyanobenzoate
• 英文别名: ethyl 3-cyano-4-hydroxybenzoate
• CAS: 34133-59-0
• 化学式: C₁₀H₉NO₃
• mdl: MFCD16251137
• 分子量: 191.186
• InChiKey: AGBGPFOWJFCHSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 储存条件：
  | 2-8℃ |

反应信息

• 作为反应物：
  描述：

  3-氰基-4-羟基苯甲酸乙酯 在 吡啶 、 四(三苯基膦)钯 、 potassium fluoride dihydrate 、 水 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 2-氰基-4-联苯羧酸
  参考文献：
  名称：

  Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5

  摘要：

  Based on SAR in the alkyne class of mGlu5 receptor negative allosteric modulators and a set of amide-based positive allosteric modulators, optimized substitution of the aryl 'b' ring was used to create substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides. Results from an mGlu5 receptor functional assay, using calcium fluorescence, revealed varying efficacies and potencies that provide evidence that subtle changes in compounds within a close structural class can have marked effects on functional activity including switches in modes of efficacy (i.e., negative to positive allosteric modulation). Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.12.110
• 作为产物：
  描述：

  benzyl 4-(benzyloxy)-3-bromobenzoate 在 四(三苯基膦)钯 、 氯化亚砜 、 palladium 10% on activated carbon 、 水 、 氢气 、 三乙胺 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 80.0 ℃ 、344.75 kPa 条件下， 反应 21.0h， 生成 3-氰基-4-羟基苯甲酸乙酯
  参考文献：
  名称：

  Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5

  摘要：

  Based on SAR in the alkyne class of mGlu5 receptor negative allosteric modulators and a set of amide-based positive allosteric modulators, optimized substitution of the aryl 'b' ring was used to create substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides. Results from an mGlu5 receptor functional assay, using calcium fluorescence, revealed varying efficacies and potencies that provide evidence that subtle changes in compounds within a close structural class can have marked effects on functional activity including switches in modes of efficacy (i.e., negative to positive allosteric modulation). Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.12.110

文献信息

• Synthesis and evaluation of 1,2,4-methyltriazines as mGluR5 antagonists
  作者：Jeremy P. Olson、Moses G. Gichinga、Elizabeth Butala、Hernan A. Navarro、Brian P. Gilmour、F. Ivy Carroll

  DOI：10.1039/c0ob01190h

  日期：——

  In previous studies we showed that 3-(substituted phenylethynyl)-5-methyl[1,2,4]triazine analogues of MPEP were potent antagonists of glutamate-mediated mobilization of internal calcium in an mGluR5 in vitro efficacy assay. In the present study we report the synthesis and evaluation of six 3-(substituted biphenylethynyl)-5-methyl[1,2,4]triazines (5a–f), and five 3-(substituted phenoxyphenylethynyl)-5-methyltriazines (6a–e). Compound 2-(4-fluorophenyl-5-[2-(5-methyl[1,2,4]triazine-3-yl)ethynyl]benzonitrile (5f) with an IC50 of 28.2 nM was the most potent analogue.

  在前期的研究中，我们展示了3-(取代苯乙炔基)-5-甲基[1,2,4]三嗪类类似物MPEP是谷氨酸介导的细胞内钙动员的强效拮抗剂，通过mGluR5体外效力检测。在本研究中，我们报道了六种3-(取代联苯乙炔基)-5-甲基[1,2,4]三嗪（5a–f）和五种3-(取代苯氧基苯乙炔基)-5-甲基三嗪（6a–e）的合成与评估。化合物2-(4-氟苯基)-5-[2-(5-甲基[1,2,4]三嗪-3-基)乙炔基]苯腈（5f），其IC50值为28.2 nM，是其中效力最强的类似物。
• Preparation of cyanophenols
  申请人：Burroughs Wellcome Co.

  公开号：US03933807A1

  公开（公告）日：1976-01-20

  A process for the preparation of a cyanophenol of formula (I) ##SPC1## wherein Z is a substituent in the 4- or 6-position with respect to the hydroxy group, characterized in that cyanide ions are reacted in a dipolar aprotic solvent with a nitrobenzene of formula (II) ##SPC2## wherein Z has the same value as in formula (I) and is a group, other than a nitro group, known to withdraw electrons in substitution reactions and which does not contain a proton capable of ionizing under the defined reaction conditions if such ionization would inhibit the electron-withdrawing effect of the group Z. In formula (I) and (II) the benzene ring is optionally substituted by one or more non electron-withdrawing groups, or by one or more electron-withdrawing groups provided that such electron-withdrawing groups are in positions other than the 4- and 6-positions with respect to the hydroxy group. The compounds of formula (I) are of value in being readily hydrolysed to the corresponding salicylic acids of formula (III) ##SPC3## certain of which have been described in the literature as possessing a variety of pharmacological properties.

  一种制备式（I）的氰苯酚的方法##SPC1##其中Z是相对于羟基的4-或6-位置的取代基，在无水极性溶剂中，氰离子与式（II）的硝基苯反应，##SPC2##其中Z的值与式（I）中的相同，并且是一种已知在取代反应中吸引电子的基团，但不含在定义的反应条件下具有离子化能力的质子，如果这种离子化会抑制基团Z的吸电子效应。在式（I）和（II）中，苯环可以选择性地被一个或多个非吸电子的基团取代，或者被一个或多个吸电子的基团取代，前提是这种吸电子的基团位于相对于羟基的4-和6-位置以外。式（I）的化合物具有价值，因为它们很容易水解成式（III）的相应水杨酸##SPC3##其中一些已经在文献中被描述为具有各种药理特性。
• Xanthine oxidase inhibitors
  申请人：Yoshida Shinichi

  公开号：US20050090472A1

  公开（公告）日：2005-04-28

  The invention relates to compounds of the following formula (I) or their salts: in which R 1 represents OR 4 or others, in which R 4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R 2 is halogen, nitro, cyano, carboxyl, or the like; R 3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR 11 , oxygen, or sulfur, in which R 11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR 12 or nitrogen, in which R 12 has the same meaning as R 3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.

  该发明涉及以下式（I）的化合物或其盐： 其中，R1表示OR4或其他，其中R4是具有1-8个碳原子的烷基，可能具有取代基或类似物；R2是卤素，硝基，氰基，羧基或类似物；R3是氢，卤素，羟基，氨基，羧基或类似物；X是NR11，氧或硫，在其中R11是氢或具有1-8个碳原子的烷基，可能具有取代基；每个Y和Z都是CR12或氮，其中R12具有与上述R3相同的含义，以及含有该化合物作为活性成分的黄嘌呤氧化酶抑制剂。
• Substituted thiazolopyrimidines as xanthine oxidase inhibitors
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US07253154B2

  公开（公告）日：2007-08-07

  The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.

  本发明涉及以下式(I)的化合物或其盐：其中，R1代表OR4或其他，其中R4是具有1-8个碳原子的烷基，可以具有取代基或类似物；R2是卤素，硝基，氰基，羧基或类似物；R3是氢，卤素，羟基，氨基，羧基或类似物；X是NR11，氧或硫，其中R11是氢或具有1-8个碳原子的烷基，可以具有取代基；Y和Z中的每一个都是CR12或氮，其中R12具有与上述R3相同的含义，并且包含该化合物作为活性成分的黄嘌呤氧化酶抑制剂。
• AMPA RECEPTOR POTENTIATORS
  申请人：Dominguez-Manzanares Esteban

  公开号：US20100010090A1

  公开（公告）日：2010-01-14

  The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

  本发明涉及公式（I）的化合物或其药学上可接受的盐，其对于与谷氨酸功能不足有关的疾病，如精神和神经疾病的治疗是有用的。